As a long-running battle over access to a pricey cystic fibrosis drug grinds on in the U.K., an advocacy group and several families have formed a buyer’s club in order to make a lower-cost version of a Vertex Pharmaceuticals (VRTX) treatment available to patients in the next few weeks.

The new buyer’s club is working with Gador, a drug maker based in Argentina, which will ship a generic version of the Orkambi medication to the U.K., where cystic fibrosis patients and their families can expect to pay roughly $25,000 a year, depending on how many people sign up. This would be 80 percent less than the approximately $132,000 that Vertex reportedly wants to charge the National Health Service in England.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy